NCT00726479 - Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis | Biotech Hunter

Timeline

Start Date

August 31, 2008

Primary Completion Date

September 30, 2008

Conditions

Pulmonary Disease, Chronic ObstructiveBronchitis, Chronic

Interventions

DRUG

BIBW 2948 BS

7.5 mg b.i.d, 15mg q.d, 15mg b.i.d

Trial Locations (24)

1219.4.01001 Boehringer Ingelheim Investigational Site, Birmingham

1219.4.01007 Boehringer Ingelheim Investigational Site, Phoenix

1219.4.01006 Boehringer Ingelheim Investigational Site, Fort Collins

1219.4.01002 Boehringer Ingelheim Investigational Site, Stamford

1219.4.01008 Boehringer Ingelheim Investigational Site, Rincon

1219.4.01003 Boehringer Ingelheim Investigational Site, Greenville

1219.4.01004 Boehringer Ingelheim Investigational Site, Spartanburg

1219.4.01005 Boehringer Ingelheim Investigational Site, Union

1219.4.3306A Boehringer Ingelheim Investigational Site, Béthune

1219.4.3306B Boehringer Ingelheim Investigational Site, Béthune

1219.4.3302A Boehringer Ingelheim Investigational Site, Marseille

1219.4.3303A Boehringer Ingelheim Investigational Site, Montpellier

1219.4.3308A Boehringer Ingelheim Investigational Site, Nice

1219.4.3307A Boehringer Ingelheim Investigational Site, Nîmes

1219.4.3307B Boehringer Ingelheim Investigational Site, Nîmes

1219.4.3301A Boehringer Ingelheim Investigational Site, Paris

1219.4.3305A Boehringer Ingelheim Investigational Site, Toulouse

1219.4.3305B Boehringer Ingelheim Investigational Site, Toulouse

1219.4.49003 Boehringer Ingelheim Investigational Site, Eisenach

1219.4.49004 Boehringer Ingelheim Investigational Site, Hamburg

1219.4.49001 Boehringer Ingelheim Investigational Site, Hanover

1219.4.49006 Boehringer Ingelheim Investigational Site, Mainz

1219.4.49005 Boehringer Ingelheim Investigational Site, Rodgau-Dudenhofen

1219.4.49002 Boehringer Ingelheim Investigational Site, Rüdersdorf